A study involving UCLA Jonsson Comprehensive Cancer Center researchers found when ribociclib, a targeted therapy drug, is added to hormone therapy there are significant invasive disease-free survival benefits in patients with early hormone-receptor (HR) positive/HER2 negative breast cancer.
From left to right: Geoffrey Shapiro, Leif Ellisen and Nancy Lin. Sitting below them is Kornelia Polyak.The Dana-Farber/Harvard Cancer Center, a cancer research consortium comprised of five of Boston’s academic medical centers, including Dana-Farber Cancer Institute and Massachusetts General Hospital, has been awarded an NCI grant to continue its Specialized Program of Research Excellence in Breast Cancer.
